Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by jojomarchon Dec 27, 2019 8:42pm
144 Views
Post# 30495907

RE:RE:RE:RE:RE:RE:RE:Warrants

RE:RE:RE:RE:RE:RE:RE:Warrants


What you have to do when you become a 10% or greater shareholder depends on whether or not you are an eligible institutional investor. If you are, then unless you are disqualified,you are eligible to use Canada’s alternative monthly reporting system (AMR). You will have to file your initial AMR report with the Canadian securities regulators within 10 days of becoming a 10% shareholder. After that, you will only need to file another AMR report within 10 days of the end of any month in which your ownership position, measured at month end, has increased or decreased by more than 2.5% from the last reported position or decreased below 10%. As an eligible institutional investor, you will also be exempt from Canada’s insider reporting requirements unless you are disqualified from the insider reporting exemption.





You are an eligible institutional investor if you are an investment manager acting on behalf of investors on a fully discretionary basis. You are also an eligible institutional investor if you are a financial institution, a pension fund, a mutual fund that is not public in Canada, an investment company registered under the Investment Company Act of 1940, a U.S. registered investment adviser or an ERISA plan.

So BARCLAYS could be acting on behalf of an investor on a fully discretionary basis .

What would you do with a PDT/PDC destruction treatment that blows KEYTRUDA and OPDIVO out of the water , would you rather try and pay 9-12 billion US dollars now or wait for the next PH1b and pay 18-21 billion . That is the beauty of this type of treatment , IMO ,instant destruction so in a PH1b you can show safely and efficacy within weeks .
Abracadabra , now you see the cancer cells ....now you don't. 
Bullboard Posts